|
KLHL15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.11110026629535E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.46329995185124E-09 |
| Normal-vs-Stage2 |
1.377720E-03 |
| Normal-vs-Stage3 |
1.12959996911854E-09 |
| Normal-vs-Stage4 |
6.82149892128336E-11 |
| Stage1-vs-Stage2 |
5.098200E-01 |
| Stage1-vs-Stage3 |
5.388000E-02 |
| Stage1-vs-Stage4 |
3.101700E-03 |
| Stage2-vs-Stage3 |
1.095190E-01 |
| Stage2-vs-Stage4 |
2.661800E-02 |
| Stage3-vs-Stage4 |
2.951600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.22168982999938E-12 |
| Normal-vs-AfricanAmerican |
1.847910E-02 |
| Normal-vs-Asian |
3.38479999584251E-09 |
| Caucasian-vs-AfricanAmerican |
6.962400E-02 |
| Caucasian-vs-Asian |
4.259000E-01 |
| AfricanAmerican-vs-Asian |
7.789700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.43719480760751E-11 |
| Normal-vs-Female |
1.53489998488965E-09 |
| Male-vs-Female |
1.029030E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.05539998962456E-09 |
| Normal-vs-Age(41-60Yrs) |
4.57600000114411E-08 |
| Normal-vs-Age(61-80Yrs) |
4.54340010058729E-10 |
| Normal-vs-Age(81-100Yrs) |
3.943100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.419600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.105400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.723000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.627800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.568800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.347400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.01559999996248E-06 |
| Classical-VS-Follicular |
8.541600E-01 |
| Classical-VS-Other |
4.132600E-01 |
| Classical-VS-Normal |
1.07950000050039E-08 |
| Tall-VS-Follicular |
2.412400E-04 |
| Tall-VS-Other |
3.024000E-01 |
| Tall-VS-Normal |
3.67395003308957E-12 |
| Follicular-VS-Other |
4.127800E-01 |
| Follicular-VS-Normal |
2.19709999971229E-07 |
| Other-VS-Normal |
4.180500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.63180000307173E-08 |
| Normal-vs-N1 |
3.08240100110879E-11 |
| N0-vs-N1 |
4.020400E-03 |
|
|
